… relapse, while 80% of patients present a de novo unresectable or metastatic disease [2].
In … -term benefit from a multimodality treatment strategy. In the arm B of the phase II AIO/FLOT3 …

… is in the center of therapy in advanced stages due to high … tients often present in preserved
general condition allowing … neoadjuvant treatment and even become unresectable [27]. …

… in the current state of a transforming therapy landscape. … regimens are investigated in current
phase III trials. The … -refractory, unresectable BTC, therapy with regorafenib could achive a …

… stage… recent knowledge on multimodality treatment for resectable (R) or borderline resectable
pancreatic ductal adenocarcinoma (BR-PDAC), with an emphasis on historical and current …

… HCC patients and the necessity of multidisciplinary management. Locoregional and multimodality
therapy for unresectable, intermediate stage … Arterial-Directed Locoregional Therapy …

… status, a course of 70 Gy in 35 fractions should be considered (45). The OMIT study is a
randomized phase II … of 1,000 consecutive stage III to IVB HNSCC previously treated with radical …

… Gy range are often necessary to treat residual or unresectable disease. Fraction size is typically
… Phase II clinical trials that are currently open to enrollment). While a multimodal therapy …

… stage IIIA and very selected ones with stage IIIB-N2 can benefit from surgical multimodality
treatment. … , is now the preferred neoadjuvant therapy in patients with resectable stage III-N2 …

… the current status of and future prospects for the treatment of GIST, highlighting the differences
between the management … The phase 3 VOYAGER trial found no significant difference in …

… Advantages of thermal ablation are the option to treat inoperable … stage I NSCLC, studies
may need to shift their focus from a single local treatment towards a multimodality treatment…